No Data
No Data
RBC Capital Maintains 89bio(ETNB.US) With Hold Rating, Maintains Target Price $12
Analysts Offer Insights on Healthcare Companies: 89bio (ETNB), Gain Therapeutics (GANX) and Boston Scientific (BSX)
Goldman Sachs Initiates 89bio(ETNB.US) With Hold Rating, Announces Target Price $11
89bio Initiated at Neutral by Goldman Sachs
Goldman Sachs Initiates Coverage On 89bio With Neutral Rating, Announces Price Target of $11
Citi Maintains 89bio(ETNB.US) With Buy Rating, Cuts Target Price to $25
104687047 : Thank you for your hardwork. Also very good choice to remove your top picks. People should do their own DD and not copy trades like those scam gurus out there
Jaguar8 OP 104687047 : yup so they will decide which one
72812736 : Thank you for your hard and selfless contributions all this time!!!!![undefined [undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36)
Dreaming Cat : Thank you for your hard work Sir
Lynn953818 : thank you very much
View more comments...